Zenocutuzumab (MCLA-128) is a bispecific humanized IgG1 antibody designed to block HER2-HER3 heterodimerization and inhibit downstream oncogenic signaling pathways, thereby exerting antitumor activity in cancers driven by HER2 and HER3, such as certain types of breast, gastric, and other solid tumors.